These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30912699)

  • 1. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
    Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
    Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
    Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
    Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
    Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
    Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
    Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R; Galal A
    BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
    Hochhaus A; Rosti G; Cross NC; Steegmann JL; le Coutre P; Ossenkoppele G; Petrov L; Masszi T; Hellmann A; Griskevicius L; Wiktor-Jedrzejczak W; Rea D; Coriu D; Brümmendorf TH; Porkka K; Saglio G; Gastl G; Müller MC; Schuld P; Di Matteo P; Pellegrino A; Dezzani L; Mahon FX; Baccarani M; Giles FJ
    Leukemia; 2016 Jan; 30(1):57-64. PubMed ID: 26437782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
    Stein AM; Martinelli G; Hughes TP; Müller MC; Beppu L; Gottardi E; Branford S; Soverini S; Woodman RC; Hochhaus A; Kim DW; Saglio G; Radich JP
    BMC Cancer; 2013 Apr; 13():173. PubMed ID: 23547655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
    Hochhaus A; Mahon FX; le Coutre P; Petrov L; Janssen JJWM; Cross NCP; Rea D; Castagnetti F; Hellmann A; Rosti G; Gattermann N; Coronel MLP; Gutierrez MAE; Garcia-Gutierrez V; Vincenzi B; Dezzani L; Giles FJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1225-1233. PubMed ID: 28224300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
    Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
    J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
    Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.
    O'Dwyer ME; Swords R; Nagler A; McMullin MF; le Coutre PD; Langabeer SE; Alvarez-Iglesias A; Fan H; Woodman RC; Giles FJ; Conneally E
    Leuk Res; 2014 Mar; 38(3):310-5. PubMed ID: 24333114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes.
    Stuckey R; Casado LF; Colomer D; Gómez-Casares MT; Casas L; García-Gutierrez V; Sastre JL; Ramírez-Payer Á; Vall-Llovera F; Goñi MÁ; Xicoy B; Godoy AC; Núñez J; Mora I; Vallansot R; López-Lorenzo JL; Palomera L; Conesa V; Noya MS; Sánchez-Guijo F; Peña A; Bautista G; Steegmann JL
    J Mol Diagn; 2020 Oct; 22(10):1217-1224. PubMed ID: 32688056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.